More and more, it seems like long-term success in chemicals and specialty materials is all about keeping an open mind toward reinvention. DuPont (NYSE:DD), for instance, is far removed from its legacy in products like gunpowder and nylon, and currently looks to advanced seed traits and nutrition as important growth markets. Likewise, DSM has moved on from coal, fertilizer and petrochemicals into areas like nutrition and biofuels.

DuPont's German cousin BASF (OTC:BASFY) is following in this path, announcing on Wednesday that it had reached an agreement to acquire Norwegian fish oil specialist Pronova for 12.50 Norwegian kroner per share, or about $845 million in enterprise value.

Credit Card Comparison: Find the credit card that is just right for you

A Cheap Deal for a High-Quality Supplement
At $845 million, BASF would be paying less than six times EV/EBITDA and only about a 4% premium to Pronova's close a day before the deal. With quite a bit of interest of late in the fish oil space, not to mention the low bid valuation, Pronova's shares are trading slightly above the bid value. Keep in mind, however, that shareholders holding more than half of Pronova's shares have agreed to the deal, though European laws give objecting minority investors more rights and leverage than in the United States.

Pronova is a leading supplier of pharmaceutical-grade fish oils - supplying the active ingredients for heart/cholesterol drug Lovaza (aka Omacor) to GlaxoSmithKline (NYSE:GSK) and Abbott Labs (NYSE:ABT). Pronova has also been actively looking to build outside of the pharmaceutical space, looking to position its fish oils into markets like clinical nutrition (parental nutrition), supplements, infant formulas and food additives - particularly those markets where especially high-grade concentrates can attract appealing pricing, and to do that they needed to turn to mergers and acquisitions.

This is not BASF's first foray into fish oil. BASF bought Equatec earlier this year, and Pronova should vault it into a leading market position in Europe and the U.S. alongside companies like Croda and DSM (which has spent about $1.6 billion over the past 18 months on Martek and Ocean Nutrition, and holds a leading share in concentrates for infant formulas).

A Deal That Says Little-to-Nothing for Amarin
One of the most controversial stocks of late in biotech has been Amarin (Nasdaq:AMRN) - an Irish biotech that has developed a highly purified omega-3 product (Vascepa) for heart disease. There has been ample debate about the sales prospects for Vascepa, including suggestions that doctors are turning away from omega-3 fatty acids/fish oil as a treatment for cholesterol and heart disease. Even more controversial is the question as to whether Amarin can secure New Chemical Entity (NCE) status from the FDA and with it, enhanced protection from potential generic competition.

Amarin has also been pegged as a company in play, with investors openly speculating on which Big Pharma may offer shareholders a lucrative buyout.

This BASF-Pronova deal, however, would seem to have little to do directly with Amarin. While it's true that Pronova supplies the key ingredient(s) for Lovaza, the drug has gone generic in Europe and will go off-patent in the U.S. in 2017. While the bulk of Pronova's revenue and profits today come from Lovaza, BASF management was quite clear that they saw the real value in the deal coming from the ongoing growth of fish oil/omega-3 fatty acids as supplements and food additives. For instance, BASF estimated that the current omega-3 concentrate market is worth about $1.1 billion today and likely to grow to over $2 billion by the end of this decade.

What's more, and I believe this is a key detail, Amarin does not produce the the ethyl-EPA that serves as the active ingredient to Vascepa. In Pronova, BASF is buying one of the largest independent producers of highly purified/concentrated omega-3 fatty acids, whereas a buyer of Amarin would primarily be acquiring the rights to market that particular formulation as a prescription treatment for heart diseases and/or high cholesterol. Consequently, I don't think Amarin investors can use the BASF-Pronova as any sort of real benchmark or comparable for a possible deal for their company.

The Bottom Line
As recent deals like Nestle's (OTC:NSRGY) bid for Pfizer's (NYSE:PFE) infant nutrition business and Reckitt Benckiser's (OTC:RBGPY) deal for Schiff Nutrition (NYSE:SHF) suggest, there is considerable interest these days in nutrition as a growth market. What's more, the M&A activity of DSM and BASF makes it sound like there's going to be considerable ongoing interest in exploiting fish oils and omega-3 fatty acids to improve the nutritional content of a wide range of food products, including infant formula.

Even with the support of major shareholders, BASF may not have Pronova wrapped up just yet. I would not be surprised to see a rival bidder step up, particularly since the valuation is not all that demanding yet. Whether a company like Bayer (OTC:BAYRY), frustrated in its attempt to buy Schiff, steps up, odds are that fish oils and omega-3 fatty acids are going to find their way into more and more clinical and consumer products in the years to come.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center